Nutrient chapter

Thymulin

Thymulin links thymic epithelial-cell function, zinc-dependent peptide bioactivity, and context-dependent immune and endocrine responses. Native peptide, zinc-free FTS and engineered formulations are separate. The molecular receptor remains unresolved; animal results are not established human treatments.

59 recorded mechanisms · 0 availability situations · 2 preserved sources. Source recording and scientific verification are labeled separately.

Read recorded mechanisms Open recursive mind map

The mechanisms

What the sources say this nutrient does, one relationship at a time. Plain wording comes first; the technical statement follows.

Zinc addition restored classical thymulin rosette-bioassay activity after Chelex metal removal, with best activation at a 1:1 metal-to-peptide ratio.
Zinc(II) ion → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Zinc addition to metal-depleted FTS", "comparator": "Metal-depleted FTS", "endpoint": "Zinc addition restored classical thymulin rosette-bioassay activity after Chelex metal removal, with best activation at a 1:1 metal-to-peptide ratio.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Purified peptide and classical rosette bioassay; Chelex metal removal followed by metal reconstitution.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
The peptide needs appropriate zinc association to be active in this assay; zinc is not shown to be consumed by signaling.
primary_references
Contribution of zinc and other metals to the biological activity of the serum thymic factor. | 1982 | DOI 10.1073/pnas.79.17.5370 | PMID 6957870 | https://doi.org/10.1073/pnas.79.17.5370
source_locator
Reviewed reference lines 23-23; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 23–23
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Purified peptide and classical rosette bioassay; Chelex metal removal followed by metal reconstitution. · Recorded from source · Recorded from source
In the foundational experiments, Chelex-mediated metal removal abolished rosette-bioassay activity, and zinc addition restored it. The best activation occurred at a 1:1 metal-to-peptide molar ratio; some other metals produced smaller recoveries. This establishes zinc-dependent activation under those conditions, not a claim that zinc is consumed with every signaling event or that all alternative complexes are inactive. [Dardenne et al., 1982](https://doi.org/10.1073/pnas.79.17.5370)
Complete structured claim and evidence
Purified FTS bound zinc with apparent Kd (5 +/- 2) x 10^-7 M at pH 7.5; binding was undetectable below pH 6 in this assay.
Zinc-free FTS nonapeptide component → Purified FTS zinc-binding affinity and metal-dependent conformation Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "pH below 6", "comparator": "pH 7.5", "endpoint": "Purified FTS bound zinc with apparent Kd (5 +/- 2) x 10^-7 M at pH 7.5; binding was undetectable below pH 6 in this assay.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Purified-system binding assay; pH 7.5 versus below pH 6.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Purified FTS bound zinc with apparent Kd (5 +/- 2) x 10^-7 M at pH 7.5; binding was undetectable below pH 6 in this assay.
primary_references
Studies on the zinc binding site to the serum thymic factor. | 1984 | DOI 10.1016/0304-4165(84)90116-8 | PMID 6538097 | https://pubmed.ncbi.nlm.nih.gov/6538097/
source_locator
Reviewed reference lines 25-25; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 25–25
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Purified-system binding assay; pH 7.5 versus below pH 6. · Recorded from source · Recorded from source
A separate binding study reported an apparent zinc dissociation constant of **(5 ± 2) × 10⁻⁷ M at pH 7.5** and no detectable binding below pH 6 under its assay conditions. Other tested metals competed for binding. These are purified-system measurements, not a threshold for dietary intake, plasma zinc or thymulin failure inside a patient. They make pH and competing ligands relevant experimental variables. [Zinc-binding study, 1984](https://pubmed.ncbi.nlm.nih.gov/6538097/)
Complete structured claim and evidence
Other tested metals competed for zinc binding to purified FTS; this is not a demonstrated dietary-metal antagonism in vivo.
Purified FTS zinc-binding affinity and metal-dependent conformation → Zinc(II) ion Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_model
Purified FTS metal-binding system; identities/concentrations of competitors not extracted in the reviewed reference.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Other tested metals competed for zinc binding to purified FTS; this is not a demonstrated dietary-metal antagonism in vivo.
primary_references
Studies on the zinc binding site to the serum thymic factor. | 1984 | DOI 10.1016/0304-4165(84)90116-8 | PMID 6538097 | https://pubmed.ncbi.nlm.nih.gov/6538097/
source_locator
Reviewed reference lines 25-25; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 25–25
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Purified FTS metal-binding system; identities/concentrations of competitors not extracted in the reviewed reference. · Recorded from source · Recorded from source
A separate binding study reported an apparent zinc dissociation constant of **(5 ± 2) × 10⁻⁷ M at pH 7.5** and no detectable binding below pH 6 under its assay conditions. Other tested metals competed for binding. These are purified-system measurements, not a threshold for dietary intake, plasma zinc or thymulin failure inside a patient. They make pH and competing ligands relevant experimental variables. [Zinc-binding study, 1984](https://pubmed.ncbi.nlm.nih.gov/6538097/)
Complete structured claim and evidence
NMR in DMSO-d6 identified 1:1 and 1:2 zinc-peptide complexes; Ser4 and the Asn9 terminal carboxylate coordinated zinc, with Ser8 participating in the 1:1 complex.
Zinc-free FTS nonapeptide component → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_model
Purified complexes in DMSO-d6; not serum or intracellular occupancy.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
NMR in DMSO-d6 identified 1:1 and 1:2 zinc-peptide complexes; Ser4 and the Asn9 terminal carboxylate coordinated zinc, with Ser8 participating in the 1:1 complex.
primary_references
NMR study of a lymphocyte differentiating thymic factor. An investigation of the Zn(II)-nonapeptide complexes (thymulin). | 1988 | DOI 10.1016/s0021-9258(18)60603-9 | PMID 3356698 | https://pubmed.ncbi.nlm.nih.gov/3356698/
source_locator
Reviewed reference lines 27-27; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 27–27
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Purified complexes in DMSO-d6; not serum or intracellular occupancy. · Recorded from source · Recorded from source
The structural qualification matters: the 1988 NMR work was performed in **DMSO-d₆**, not blood. It identified 1:1 and 1:2 zinc–peptide complexes depending on the mixture. Coordination involved Ser4 and the Asn9 **terminal carboxylate**, with Ser8 also participating in the 1:1 complex. This supports a metal-dependent conformation but does not establish the distribution of complexes in living tissues. “One zinc per active peptide” should therefore describe a conventional preparation/activation model, not proven universal physiological occupancy. [NMR study](https://pubmed.ncbi.nlm.nih.gov/3356698/)
Complete structured claim and evidence
Thymic epithelial cells produce thymulin; metal-dependent antibody recognition must be distinguished from peptide quantity and biological activity.
Human thymic epithelial cells → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_model
Thymic epithelial cells and metal-sensitive antibody assays.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymic epithelial cells produce thymulin; metal-dependent antibody recognition must be distinguished from peptide quantity and biological activity.
primary_references
A zinc-dependent epitope on the molecule of thymulin, a thymic hormone. | 1985 | DOI 10.1073/pnas.82.20.7035 | PMID 2413455 | https://doi.org/10.1073/pnas.82.20.7035
source_locator
Reviewed reference lines 33-33; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 33–33
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Thymic epithelial cells and metal-sensitive antibody assays. · Recorded from source · Recorded from source
Thymic epithelial cells (TECs) are the established source. Production, secretion and metal-dependent activity should be represented as distinct processes. Antibody recognition of thymulin in TECs and serum also depends on the assay's sensitivity to metal-associated conformation. [TEC and antibody study](https://doi.org/10.1073/pnas.82.20.7035)
Complete structured claim and evidence
IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.
Human interleukin-1 alpha / IL1A → Cellular zinc influx Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "IL-1 exposure", "comparator": "Untreated cultures", "endpoint": "IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Cultured human TECs; IL-1 exposure, uptake assay.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Cultured human TECs; IL-1 exposure, uptake assay. · Recorded from source · Recorded from source
In cultured human TECs, **IL-1α and IL-1β increased zinc uptake, metallothionein mRNA and secretion of biologically active thymulin**. Part of the IL-1 effect on zinc uptake occurred independently of proliferation. Metallothionein was proposed as an intracellular zinc donor; direct transfer from a defined metallothionein molecule to FTS was not resolved by these observations. Do not turn that proposal into an established transfer reaction. [Coto et al., 1992](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.
Human interleukin-1 alpha / IL1A → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "IL-1 exposure", "comparator": "Untreated cultures", "endpoint": "IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Cultured human TECs; bioactivity readout, not native precursor-gene discovery.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Cultured human TECs; bioactivity readout, not native precursor-gene discovery. · Recorded from source · Recorded from source
In cultured human TECs, **IL-1α and IL-1β increased zinc uptake, metallothionein mRNA and secretion of biologically active thymulin**. Part of the IL-1 effect on zinc uptake occurred independently of proliferation. Metallothionein was proposed as an intracellular zinc donor; direct transfer from a defined metallothionein molecule to FTS was not resolved by these observations. Do not turn that proposal into an established transfer reaction. [Coto et al., 1992](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.
Interleukin-1 beta / IL1B → Cellular zinc influx Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "IL-1 exposure", "comparator": "Untreated cultures", "endpoint": "IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Cultured human TECs; IL-1 exposure, uptake assay.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Cultured human TECs; IL-1 exposure, uptake assay. · Recorded from source · Recorded from source
In cultured human TECs, **IL-1α and IL-1β increased zinc uptake, metallothionein mRNA and secretion of biologically active thymulin**. Part of the IL-1 effect on zinc uptake occurred independently of proliferation. Metallothionein was proposed as an intracellular zinc donor; direct transfer from a defined metallothionein molecule to FTS was not resolved by these observations. Do not turn that proposal into an established transfer reaction. [Coto et al., 1992](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.
Interleukin-1 beta / IL1B → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "IL-1 exposure", "comparator": "Untreated cultures", "endpoint": "IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Cultured human TECs; bioactivity readout, not native precursor-gene discovery.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Cultured human TECs; bioactivity readout, not native precursor-gene discovery. · Recorded from source · Recorded from source
In cultured human TECs, **IL-1α and IL-1β increased zinc uptake, metallothionein mRNA and secretion of biologically active thymulin**. Part of the IL-1 effect on zinc uptake occurred independently of proliferation. Metallothionein was proposed as an intracellular zinc donor; direct transfer from a defined metallothionein molecule to FTS was not resolved by these observations. Do not turn that proposal into an established transfer reaction. [Coto et al., 1992](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
IL-1 increased metallothionein mRNA in human TEC cultures; direct metallothionein-to-FTS zinc transfer remained proposed rather than measured.
Interleukin-1 beta / IL1B → Metallothioneins Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "IL-1 exposure", "comparator": "Untreated cultures", "endpoint": "IL-1 increased metallothionein mRNA in human TEC cultures; direct metallothionein-to-FTS zinc transfer remained proposed rather than measured.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Human TECs; metallothionein transcript measurement, isoform unresolved.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-1 increased metallothionein mRNA in human TEC cultures; direct metallothionein-to-FTS zinc transfer remained proposed rather than measured.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human TECs; metallothionein transcript measurement, isoform unresolved. · Recorded from source · Recorded from source
In cultured human TECs, **IL-1α and IL-1β increased zinc uptake, metallothionein mRNA and secretion of biologically active thymulin**. Part of the IL-1 effect on zinc uptake occurred independently of proliferation. Metallothionein was proposed as an intracellular zinc donor; direct transfer from a defined metallothionein molecule to FTS was not resolved by these observations. Do not turn that proposal into an established transfer reaction. [Coto et al., 1992](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
Stressed metallothionein-overexpressing mice had reduced active thymulin despite normal-range plasma zinc and preserved zinc-recoverable thymulin activity.
Experimental mouse metallothionein overexpression → Mouse thymulin bioassay activity Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Study control mice overexpression · Experimental mouse metallothionein overexpression Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Metallothionein overexpression under stress", "comparator": "Study control mice", "endpoint": "Stressed metallothionein-overexpressing mice had reduced active thymulin despite normal-range plasma zinc and preserved zinc-recoverable thymulin activity.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "mouse-metallothionein-overexpression", "state": "overexpression"}, {"entity_slug": null, "state": "experimental stress"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Stressed metallothionein-overexpressing mice; liver zinc storage, plasma zinc and thymic changes were distinct measurements.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Stressed metallothionein-overexpressing mice had reduced active thymulin despite normal-range plasma zinc and preserved zinc-recoverable thymulin activity.
primary_references
Metallothioneins (I+II) and thyroid–thymus axis efficiency in old mice: role of corticosterone and zinc supply | 2002 | DOI 10.1016/S0047-6374(01)00414-6 | PMID 11850030 | https://pmc.ncbi.nlm.nih.gov/articles/PMC7127331/
source_locator
Reviewed reference lines 48-48; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 48–48
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Stressed metallothionein-overexpressing mice; liver zinc storage, plasma zinc and thymic changes were distinct measurements. · Recorded from source · Recorded from source
Metallothionein is not simply beneficial or harmful. A 2002 mouse study found that stressed metallothionein-overexpressing animals had reduced active thymulin and NK-cell activity despite normal-range plasma zinc and preserved zinc-recoverable thymulin activity. Higher corticosterone, liver zinc–metallothionein and reduced thymic cortex accompanied the phenotype. This supports investigating **zinc distribution and stress**, but does not prove that metallothionein directly starved the peptide in TECs or mediated every immune change. Liver storage, TEC delivery and serum bioactivity are different compartments and measurements. [Mouse stress and zinc-distribution study](https://pmc.ncbi.nlm.nih.gov/articles/PMC7127331/)
Complete structured claim and evidence
Experimental met-FTS gene delivery expresses an engineered analogue; it does not identify the native human FTS precursor gene.
Engineered methionine-FTS analogue → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_model
Engineered synthetic expression study.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Experimental met-FTS gene delivery expresses an engineered analogue; it does not identify the native human FTS precursor gene.
primary_references
Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats. | 2006 | DOI 10.1038/sj.gt.3302775 | PMID 16617301 | https://doi.org/10.1038/sj.gt.3302775
source_locator
Reviewed reference lines 50-50; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 50–50
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Engineered synthetic expression study. · Recorded from source · Recorded from source
Identification of the peptide does not identify its full native biosynthetic pathway. No sufficiently established endogenous precursor gene and processing sequence was verified in this review. The synthetic **met-FTS** construct used for experimental gene delivery is an engineered analogue; successful expression is not discovery of the native human gene. [Synthetic expression study](https://doi.org/10.1038/sj.gt.3302775)
Complete structured claim and evidence
Radioligand assays found specific FTS-binding sites with apparent Kd near 3 nM in 1301 and HSB2 cells; several other tested cell lines lacked comparable binding.
Zinc-free FTS nonapeptide component → Specific FTS binding in human 1301 and HSB2 lymphoblastoid cells Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Radiolabeled FTS binding in 1301/HSB2", "comparator": "Other tested cell lines and assay controls", "endpoint": "Radioligand assays found specific FTS-binding sites with apparent Kd near 3 nM in 1301 and HSB2 cells; several other tested cell lines lacked comparable binding.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Human lymphoblastoid cell lines; binding protein identity unresolved.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Radioligand assays found specific FTS-binding sites with apparent Kd near 3 nM in 1301 and HSB2 cells; several other tested cell lines lacked comparable binding.
primary_references
Specific receptors for the serum thymic factor (FTS) in lymphoblastoid cultured cell lines. | 1980 | DOI 10.1073/pnas.77.5.2861 | PMID 6248873 | https://doi.org/10.1073/pnas.77.5.2861
source_locator
Reviewed reference lines 54-54; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 54–54
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human lymphoblastoid cell lines; binding protein identity unresolved. · Recorded from source · Recorded from source
Historical radioligand experiments found specific FTS-binding sites in the human lymphoblastoid lines **1301 and HSB2**, with an apparent dissociation constant near 3 nM. Several other tested cell lines lacked comparable binding. This supports selective cellular recognition, but does not identify the binding protein or establish a receptor family. The cellular binding constant and the zinc–peptide binding constant above describe different interactions. [Pleau et al., 1980](https://doi.org/10.1073/pnas.77.5.2861)
Complete structured claim and evidence
Induction of IL-2-receptor-positive lymphocytes was used as a functional zinc-thymulin readout; it is not equivalent to IL-2 secretion.
Thymulin → Human IL-2-receptor-positive lymphocyte proportion Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Zinc-thymulin exposure", "comparator": "Study control", "endpoint": "Induction of IL-2-receptor-positive lymphocytes was used as a functional zinc-thymulin readout; it is not equivalent to IL-2 secretion.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Human lymphocyte functional readout in TEC study.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Induction of IL-2-receptor-positive lymphocytes was used as a functional zinc-thymulin readout; it is not equivalent to IL-2 secretion.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 56-56; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 56–56
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human lymphocyte functional readout in TEC study. · Recorded from source · Recorded from source
The human TEC study used induction of IL-2-receptor-positive lymphocytes as a functional readout. It also found that zinc–thymulin increased nuclear PKC activity in isolated lymphocyte nuclei **when IL-1 was present**, but not without IL-1. Keep the nuclear preparation, cytokine requirement and readout attached to that result. It does not establish an unconditional receptor → PKC → IL-2-production pathway in intact T cells. [Human-cell study](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
Zinc-thymulin increased nuclear PKC activity in isolated lymphocyte nuclei when IL-1 was present, but not without IL-1.
Thymulin → Human lymphocyte nuclear PKC activity, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
Zinc-thymulin without IL-1 zinc-thymulin exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Zinc-thymulin with IL-1", "comparator": "Zinc-thymulin without IL-1", "endpoint": "Zinc-thymulin increased nuclear PKC activity in isolated lymphocyte nuclei when IL-1 was present, but not without IL-1.", "effect_direction": "mixed", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "zinc-thymulin exposure"}, {"entity_slug": null, "state": "IL-1 present"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Isolated human lymphocyte nuclei; cytokine-dependent effect, not unconditional intact-cell signaling.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Zinc-thymulin increased nuclear PKC activity in isolated lymphocyte nuclei when IL-1 was present, but not without IL-1.
primary_references
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. | 1992 | DOI 10.1073/pnas.89.16.7752 | PMID 1502195 | https://doi.org/10.1073/pnas.89.16.7752
source_locator
Reviewed reference lines 56-56; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 56–56
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated human lymphocyte nuclei; cytokine-dependent effect, not unconditional intact-cell signaling. · Recorded from source · Recorded from source
The human TEC study used induction of IL-2-receptor-positive lymphocytes as a functional readout. It also found that zinc–thymulin increased nuclear PKC activity in isolated lymphocyte nuclei **when IL-1 was present**, but not without IL-1. Keep the nuclear preparation, cytokine requirement and readout attached to that result. It does not establish an unconditional receptor → PKC → IL-2-production pathway in intact T cells. [Human-cell study](https://doi.org/10.1073/pnas.89.16.7752)
Complete structured claim and evidence
Thymulin produced opposite IL-2-receptor-positive lymphocyte responses in normal versus hypothyroid chicken strains.
Thymulin → Chicken IL-2-receptor-positive lymphocyte proportion Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin in normal versus hypothyroid chickens", "comparator": "Corresponding strain controls", "endpoint": "Thymulin produced opposite IL-2-receptor-positive lymphocyte responses in normal versus hypothyroid chicken strains.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Avian lymphocytes; normal and hypothyroid strains, not human efficacy.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin produced opposite IL-2-receptor-positive lymphocyte responses in normal versus hypothyroid chicken strains.
primary_references
The effect of thymulin on avian IL-2 receptor expression. | 2000 | DOI 10.1016/s0192-0561(00)00051-5 | PMID 11090697 | https://pubmed.ncbi.nlm.nih.gov/11090697/
source_locator
Reviewed reference lines 58-58; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 58–58
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Avian lymphocytes; normal and hypothyroid strains, not human efficacy. · Recorded from source · Recorded from source
Context dependence extends to target-cell markers: an avian study reported opposite changes in the proportion of IL-2-receptor-positive lymphocytes in normal versus hypothyroid chicken strains. This cannot be transferred directly to human disease, but it prevents a universal “thymulin increases IL-2 receptors” rule. [Avian IL-2-receptor experiment](https://pubmed.ncbi.nlm.nih.gov/11090697/)
Complete structured claim and evidence
Thymulin increased proinflammatory cytokine secretion in unstimulated RAW264.7 macrophages. In LPS-stimulated cells, thymulin alone did not change the measured cytokine secretion.
Thymulin → Mouse macrophage proinflammatory cytokine secretion Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin with or without LPS", "comparator": "Matched stimulus-only/untreated controls", "endpoint": "Thymulin increased proinflammatory cytokine secretion in unstimulated RAW264.7 macrophages. In LPS-stimulated cells, thymulin alone did not change the measured cytokine secretion.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse RAW264.7 macrophages; resting versus LPS stimulation.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin increased proinflammatory cytokine secretion in unstimulated RAW264.7 macrophages. In LPS-stimulated cells, thymulin alone did not change the measured cytokine secretion.
primary_references
Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. | 2011 | DOI 10.1517/14728222.2011.641952 | PMID 22148922 | https://pubmed.ncbi.nlm.nih.gov/22148922/
source_locator
Reviewed reference lines 68-68; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 68–68
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse RAW264.7 macrophages; resting versus LPS stimulation. · Recorded from source · Recorded from source
| RAW264.7 macrophages, unstimulated versus LPS-stimulated | In resting cells, thymulin increased proinflammatory cytokine secretion. In LPS-stimulated cells, it reduced SAPK/JNK activity but not NF-κB activity; peptide alone did not change the measured cytokine secretion. HSP72 increased. | Preserve the resting/stimulated contrast. Thymopentin was also studied and requires separate attribution. [2011 experiment](https://pubmed.ncbi.nlm.nih.gov/22148922/) |
Complete structured claim and evidence
Thymulin reduced SAPK/JNK activity in LPS-stimulated RAW264.7 cells.
Thymulin → Mouse JNK assay pool, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS alone added peptide · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS alone", "endpoint": "Thymulin reduced SAPK/JNK activity in LPS-stimulated RAW264.7 cells.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "added peptide"}, {"entity_slug": null, "state": "LPS stimulation"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse RAW264.7 macrophages stimulated with LPS; isoform unresolved.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin reduced SAPK/JNK activity in LPS-stimulated RAW264.7 cells.
primary_references
Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. | 2011 | DOI 10.1517/14728222.2011.641952 | PMID 22148922 | https://pubmed.ncbi.nlm.nih.gov/22148922/
source_locator
Reviewed reference lines 68-68; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 68–68
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse RAW264.7 macrophages stimulated with LPS; isoform unresolved. · Recorded from source · Recorded from source
| RAW264.7 macrophages, unstimulated versus LPS-stimulated | In resting cells, thymulin increased proinflammatory cytokine secretion. In LPS-stimulated cells, it reduced SAPK/JNK activity but not NF-κB activity; peptide alone did not change the measured cytokine secretion. HSP72 increased. | Preserve the resting/stimulated contrast. Thymopentin was also studied and requires separate attribution. [2011 experiment](https://pubmed.ncbi.nlm.nih.gov/22148922/) |
Complete structured claim and evidence
Thymulin did not reduce the reported NF-kappa-B activation readout in LPS-stimulated RAW264.7 macrophages; this is not evidence for unconditional NF-kappa-B inhibition.
Thymulin → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS alone added peptide · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS alone", "endpoint": "Thymulin did not reduce the reported NF-kappa-B activation readout in LPS-stimulated RAW264.7 macrophages; this is not evidence for unconditional NF-kappa-B inhibition.", "effect_direction": "no_detected_change", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "added peptide"}, {"entity_slug": null, "state": "LPS stimulation"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse RAW264.7 macrophages; LPS stimulation; endpoint retained at reported pathway level.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin did not reduce the reported NF-kappa-B activation readout in LPS-stimulated RAW264.7 macrophages; this is not evidence for unconditional NF-kappa-B inhibition.
primary_references
Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. | 2011 | DOI 10.1517/14728222.2011.641952 | PMID 22148922 | https://pubmed.ncbi.nlm.nih.gov/22148922/
source_locator
Reviewed reference lines 68-68; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 68–68
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse RAW264.7 macrophages; LPS stimulation; endpoint retained at reported pathway level. · Recorded from source · Recorded from source
| RAW264.7 macrophages, unstimulated versus LPS-stimulated | In resting cells, thymulin increased proinflammatory cytokine secretion. In LPS-stimulated cells, it reduced SAPK/JNK activity but not NF-κB activity; peptide alone did not change the measured cytokine secretion. HSP72 increased. | Preserve the resting/stimulated contrast. Thymopentin was also studied and requires separate attribution. [2011 experiment](https://pubmed.ncbi.nlm.nih.gov/22148922/) |
Complete structured claim and evidence
Thymulin increased HSP72 in the macrophage experiment.
Thymulin → Mouse HSP72 assay pool Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin exposure", "comparator": "Study control", "endpoint": "Thymulin increased HSP72 in the macrophage experiment.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse RAW264.7 macrophages; protein readout.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin increased HSP72 in the macrophage experiment.
primary_references
Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. | 2011 | DOI 10.1517/14728222.2011.641952 | PMID 22148922 | https://pubmed.ncbi.nlm.nih.gov/22148922/
source_locator
Reviewed reference lines 68-68; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 68–68
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse RAW264.7 macrophages; protein readout. · Recorded from source · Recorded from source
| RAW264.7 macrophages, unstimulated versus LPS-stimulated | In resting cells, thymulin increased proinflammatory cytokine secretion. In LPS-stimulated cells, it reduced SAPK/JNK activity but not NF-κB activity; peptide alone did not change the measured cytokine secretion. HSP72 increased. | Preserve the resting/stimulated contrast. Thymopentin was also studied and requires separate attribution. [2011 experiment](https://pubmed.ncbi.nlm.nih.gov/22148922/) |
Complete structured claim and evidence
Thymulin increased cAMP in LPS-challenged fetal rat alveolar type II cells.
Thymulin → Intracellular cyclic AMP content Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS-matched control", "endpoint": "Thymulin increased cAMP in LPS-challenged fetal rat alveolar type II cells.", "effect_direction": "increase", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": null, "state": "LPS challenge"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin increased cAMP in LPS-challenged fetal rat alveolar type II cells.
primary_references
Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro. | 2009 | DOI 10.1016/j.molimm.2009.09.034 | PMID 19850345 | https://pubmed.ncbi.nlm.nih.gov/19850345/
source_locator
Reviewed reference lines 69-69; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 69–69
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper. · Recorded from source · Recorded from source
| Fetal rat alveolar type II cells challenged with LPS | Thymulin increased cAMP, reduced NF-κB nuclear signaling and reduced IL-1β release; IL-6 and TNF-α were not similarly suppressed. | Zinc alone also changed cytokine outputs. cAMP-associated effects do not identify a GPCR or establish sole mediation. This paper is not the retracted hippocampal paper discussed below. [2009 experiment](https://pubmed.ncbi.nlm.nih.gov/19850345/) |
Complete structured claim and evidence
Thymulin reduced NF-kappa-B nuclear signaling in LPS-challenged fetal rat alveolar type II cells.
Thymulin → Rat NF-kappa-B nuclear signaling Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS-matched control", "endpoint": "Thymulin reduced NF-kappa-B nuclear signaling in LPS-challenged fetal rat alveolar type II cells.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": null, "state": "LPS challenge"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin reduced NF-kappa-B nuclear signaling in LPS-challenged fetal rat alveolar type II cells.
primary_references
Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro. | 2009 | DOI 10.1016/j.molimm.2009.09.034 | PMID 19850345 | https://pubmed.ncbi.nlm.nih.gov/19850345/
source_locator
Reviewed reference lines 69-69; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 69–69
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper. · Recorded from source · Recorded from source
| Fetal rat alveolar type II cells challenged with LPS | Thymulin increased cAMP, reduced NF-κB nuclear signaling and reduced IL-1β release; IL-6 and TNF-α were not similarly suppressed. | Zinc alone also changed cytokine outputs. cAMP-associated effects do not identify a GPCR or establish sole mediation. This paper is not the retracted hippocampal paper discussed below. [2009 experiment](https://pubmed.ncbi.nlm.nih.gov/19850345/) |
Complete structured claim and evidence
Thymulin reduced IL-1 beta release in LPS-challenged fetal rat alveolar type II cells.
Thymulin → Rat interleukin-1 beta / Il1b Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS-matched control", "endpoint": "Thymulin reduced IL-1 beta release in LPS-challenged fetal rat alveolar type II cells.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": null, "state": "LPS challenge"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin reduced IL-1 beta release in LPS-challenged fetal rat alveolar type II cells.
primary_references
Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro. | 2009 | DOI 10.1016/j.molimm.2009.09.034 | PMID 19850345 | https://pubmed.ncbi.nlm.nih.gov/19850345/
source_locator
Reviewed reference lines 69-69; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 69–69
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper. · Recorded from source · Recorded from source
| Fetal rat alveolar type II cells challenged with LPS | Thymulin increased cAMP, reduced NF-κB nuclear signaling and reduced IL-1β release; IL-6 and TNF-α were not similarly suppressed. | Zinc alone also changed cytokine outputs. cAMP-associated effects do not identify a GPCR or establish sole mediation. This paper is not the retracted hippocampal paper discussed below. [2009 experiment](https://pubmed.ncbi.nlm.nih.gov/19850345/) |
Complete structured claim and evidence
IL-6 was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.
Thymulin → Rat interleukin-6 / Il6 Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS-matched control", "endpoint": "IL-6 was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.", "effect_direction": "no_detected_change", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": null, "state": "LPS challenge"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IL-6 was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.
primary_references
Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro. | 2009 | DOI 10.1016/j.molimm.2009.09.034 | PMID 19850345 | https://pubmed.ncbi.nlm.nih.gov/19850345/
source_locator
Reviewed reference lines 69-69; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 69–69
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper. · Recorded from source · Recorded from source
| Fetal rat alveolar type II cells challenged with LPS | Thymulin increased cAMP, reduced NF-κB nuclear signaling and reduced IL-1β release; IL-6 and TNF-α were not similarly suppressed. | Zinc alone also changed cytokine outputs. cAMP-associated effects do not identify a GPCR or establish sole mediation. This paper is not the retracted hippocampal paper discussed below. [2009 experiment](https://pubmed.ncbi.nlm.nih.gov/19850345/) |
Complete structured claim and evidence
TNF-alpha was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.
Thymulin → Rat tumor necrosis factor alpha / Tnf Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
LPS-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus LPS", "comparator": "LPS-matched control", "endpoint": "TNF-alpha was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.", "effect_direction": "no_detected_change", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": null, "state": "LPS challenge"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
TNF-alpha was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.
primary_references
Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro. | 2009 | DOI 10.1016/j.molimm.2009.09.034 | PMID 19850345 | https://pubmed.ncbi.nlm.nih.gov/19850345/
source_locator
Reviewed reference lines 69-69; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 69–69
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat alveolar type II cells challenged with LPS; zinc-alone controls also affected cytokines. Distinct from the retracted hippocampal paper. · Recorded from source · Recorded from source
| Fetal rat alveolar type II cells challenged with LPS | Thymulin increased cAMP, reduced NF-κB nuclear signaling and reduced IL-1β release; IL-6 and TNF-α were not similarly suppressed. | Zinc alone also changed cytokine outputs. cAMP-associated effects do not identify a GPCR or establish sole mediation. This paper is not the retracted hippocampal paper discussed below. [2009 experiment](https://pubmed.ncbi.nlm.nih.gov/19850345/) |
Complete structured claim and evidence
Combined thymulin/zinc increased IL-6 in the developmental lung experiments.
Thymulin → Rat interleukin-6 / Il6 Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary abstract plus selected publisher results inspected; full XML not obtained.
experimental_condition
Matched experimental control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Matched experimental control joint zinc exposure · Zinc(II) ion Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Combined thymulin and zinc", "comparator": "Matched experimental control", "endpoint": "Combined thymulin/zinc increased IL-6 in the developmental lung experiments.", "effect_direction": "increase", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": "zinc-ion", "state": "joint zinc exposure"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat lung explants; A549 cells studied separately; oxygen-dependent conditions and endpoints retained in source.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Combined thymulin/zinc increased IL-6 in the developmental lung experiments.
primary_references
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 | DOI 10.1152/ajplung.00401.2002 | PMID 12639846 | https://doi.org/10.1152/ajplung.00401.2002
source_locator
Reviewed reference lines 70-70; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 70–70
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat lung explants; A549 cells studied separately; oxygen-dependent conditions and endpoints retained in source. · Recorded from source · Recorded from source
| Fetal rat lung explants and A549 lung cells, oxygen-dependent conditions | Combined thymulin/zinc exposure increased IL-6 and reduced TNF protein, with p38/MAPKAPK2 and transcription-factor responses. In explants, IL-6 antisense interfered with mesenchymal growth and FGF9-associated effects. | Increased IL-6 here is a developmental response; TNF transcript and protein need separate records. Joint peptide/zinc treatment cannot automatically be attributed to peptide alone. [2004 experiment](https://doi.org/10.1152/ajplung.00401.2002) |
Complete structured claim and evidence
Combined thymulin/zinc reduced TNF protein in the developmental lung experiments; transcript and protein effects must remain separate.
Thymulin → Rat tumor necrosis factor alpha / Tnf Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary abstract plus selected publisher results inspected; full XML not obtained.
experimental_condition
Matched experimental control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Matched experimental control joint zinc exposure · Zinc(II) ion Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Combined thymulin and zinc", "comparator": "Matched experimental control", "endpoint": "Combined thymulin/zinc reduced TNF protein in the developmental lung experiments; transcript and protein effects must remain separate.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": "zinc-ion", "state": "joint zinc exposure"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Fetal rat lung explants; A549 cells studied separately; oxygen-dependent conditions and endpoints retained in source.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Combined thymulin/zinc reduced TNF protein in the developmental lung experiments; transcript and protein effects must remain separate.
primary_references
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 | DOI 10.1152/ajplung.00401.2002 | PMID 12639846 | https://doi.org/10.1152/ajplung.00401.2002
source_locator
Reviewed reference lines 70-70; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 70–70
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Fetal rat lung explants; A549 cells studied separately; oxygen-dependent conditions and endpoints retained in source. · Recorded from source · Recorded from source
| Fetal rat lung explants and A549 lung cells, oxygen-dependent conditions | Combined thymulin/zinc exposure increased IL-6 and reduced TNF protein, with p38/MAPKAPK2 and transcription-factor responses. In explants, IL-6 antisense interfered with mesenchymal growth and FGF9-associated effects. | Increased IL-6 here is a developmental response; TNF transcript and protein need separate records. Joint peptide/zinc treatment cannot automatically be attributed to peptide alone. [2004 experiment](https://doi.org/10.1152/ajplung.00401.2002) |
Complete structured claim and evidence
In repeated-LPS mice, free thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.
Thymulin → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, free thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, free thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In repeated-LPS mice, free thymulin reduced reported splenic jnk phosphorylation/signaling readouts.
Thymulin → Mouse JNK assay pool, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, free thymulin reduced reported splenic jnk phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, free thymulin reduced reported splenic jnk phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In repeated-LPS mice, free thymulin reduced reported splenic p38 phosphorylation/signaling readouts.
Thymulin → Mouse p38 phosphorylation, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, free thymulin reduced reported splenic p38 phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, free thymulin reduced reported splenic p38 phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.
PBCA nanoparticle-bound thymulin formulation → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.
PBCA nanoparticle-bound thymulin formulation → Mouse JNK assay pool, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.
PBCA nanoparticle-bound thymulin formulation → Mouse p38 phosphorylation, isoform unresolved Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.
primary_references
Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
source_locator
Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source
| Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
Complete structured claim and evidence
In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.
PBCA nanoparticle-bound thymulin formulation → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_contrast
{"intervention": "PBCA-thymulin", "comparator": "Disease controls and free-peptide comparison", "endpoint": "In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse EAE; formulation, phosphorylation site and day-dependent endpoints.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.
primary_references
Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice | 2019 | DOI 10.3390/ijms20215374 | PMID 31671728 | https://doi.org/10.3390/ijms20215374
source_locator
Reviewed reference lines 72-72; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 72–72
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse EAE; formulation, phosphorylation site and day-dependent endpoints. · Recorded from source · Recorded from source
| Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |
Complete structured claim and evidence
The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.
PBCA nanoparticle-bound thymulin formulation → Mouse measured p53-pathway response Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_contrast
{"intervention": "Thymulin formulation treatment", "comparator": "Disease control", "endpoint": "The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse EAE; not evidence that all p53 functions are unaffected.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.
primary_references
Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice | 2019 | DOI 10.3390/ijms20215374 | PMID 31671728 | https://doi.org/10.3390/ijms20215374
source_locator
Reviewed reference lines 72-72; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 72–72
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse EAE; not evidence that all p53 functions are unaffected. · Recorded from source · Recorded from source
| Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |
Complete structured claim and evidence
Thymulin with equimolar zinc reduced I-kappa-B-alpha phosphorylation and p65 DNA binding in conditioned mouse macrophages.
Thymulin → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Zinc-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Zinc-matched control equimolar zinc · Zinc(II) ion Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus equimolar zinc", "comparator": "Zinc-matched control", "endpoint": "Thymulin with equimolar zinc reduced I-kappa-B-alpha phosphorylation and p65 DNA binding in conditioned mouse macrophages.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": "zinc-ion", "state": "equimolar zinc"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse macrophages conditioned for one week, then challenged with LPS; human PBMC experiments used 24-hour pretreatment and are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin with equimolar zinc reduced I-kappa-B-alpha phosphorylation and p65 DNA binding in conditioned mouse macrophages.
primary_references
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. | 2026 | DOI 10.1038/s41467-026-75383-0 | PMID 42481458 | https://www.nature.com/articles/s41467-026-75383-0
source_locator
Reviewed reference lines 78-78; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 78–78
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse macrophages conditioned for one week, then challenged with LPS; human PBMC experiments used 24-hour pretreatment and are separate. · Recorded from source · Recorded from source
The 2026 Nature Communications study used **thymulin plus equimolar zinc versus zinc-matched controls**. Human PBMCs received 24-hour treatment before stimulated cytokine assessment. Mouse macrophages were conditioned during a week of differentiation, then challenged with LPS. Reduced IκBα phosphorylation, p65 DNA binding and inflammatory cytokine responses were reported. Mutation of an NF-κB site in an Il6 reporter removed the inhibitory reporter effect.
Complete structured claim and evidence
Mutation of an NF-kappa-B site in the mouse Il6 reporter removed the inhibitory reporter effect of thymulin treatment.
Thymulin → Mouse Il6 promoter NF-kappa-B reporter response Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Zinc-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Zinc-matched control equimolar zinc · Zinc(II) ion Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin plus equimolar zinc", "comparator": "Zinc-matched control", "endpoint": "Mutation of an NF-kappa-B site in the mouse Il6 reporter removed the inhibitory reporter effect of thymulin treatment.", "effect_direction": "mixed", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": "zinc-ion", "state": "equimolar zinc"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse macrophages conditioned for one week, then challenged with LPS; human PBMC experiments used 24-hour pretreatment and are separate.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Mutation of an NF-kappa-B site in the mouse Il6 reporter removed the inhibitory reporter effect of thymulin treatment.
primary_references
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. | 2026 | DOI 10.1038/s41467-026-75383-0 | PMID 42481458 | https://www.nature.com/articles/s41467-026-75383-0
source_locator
Reviewed reference lines 78-78; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 78–78
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse macrophages conditioned for one week, then challenged with LPS; human PBMC experiments used 24-hour pretreatment and are separate. · Recorded from source · Recorded from source
The 2026 Nature Communications study used **thymulin plus equimolar zinc versus zinc-matched controls**. Human PBMCs received 24-hour treatment before stimulated cytokine assessment. Mouse macrophages were conditioned during a week of differentiation, then challenged with LPS. Reduced IκBα phosphorylation, p65 DNA binding and inflammatory cytokine responses were reported. Mutation of an NF-κB site in an Il6 reporter removed the inhibitory reporter effect.
Complete structured claim and evidence
Thymulin treatment improved antitumor immune responses and anti-PD-L1 responsiveness in aged tumor-bearing mice.
Thymulin → Antitumor immune response in aged mice Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_condition
Zinc-matched control peptide exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Zinc-matched control equimolar zinc · Zinc(II) ion Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "Thymulin regimen", "comparator": "Zinc-matched control", "endpoint": "Thymulin treatment improved antitumor immune responses and anti-PD-L1 responsiveness in aged tumor-bearing mice.", "effect_direction": "increase", "combination": "joint", "conditions": [{"entity_slug": "thymulin", "state": "peptide exposure"}, {"entity_slug": "zinc-ion", "state": "equimolar zinc"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Aged mouse tumors; thymulin plus equimolar zinc versus zinc-matched controls, including anti-PD-L1 combinations.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin treatment improved antitumor immune responses and anti-PD-L1 responsiveness in aged tumor-bearing mice.
primary_references
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. | 2026 | DOI 10.1038/s41467-026-75383-0 | PMID 42481458 | https://www.nature.com/articles/s41467-026-75383-0
source_locator
Reviewed reference lines 80-80; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 80–80
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Aged mouse tumors; thymulin plus equimolar zinc versus zinc-matched controls, including anti-PD-L1 combinations. · Recorded from source · Recorded from source
In aged tumor-bearing mice, treatment improved antitumor immune responses and anti-PD-L1 responsiveness. These findings support a downstream NF-κB-associated mechanism in those models. They do not demonstrate immediate direct inhibition of IKK, identify a thymulin receptor, show human cancer efficacy, or establish zinc deficiency as the cause of the tumors. [2026 primary study](https://www.nature.com/articles/s41467-026-75383-0)
Complete structured claim and evidence
Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.
Engineered thymulin-expression plasmid delivery → Mouse allergic airway inflammation and remodeling Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_contrast
{"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.
primary_references
Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
source_locator
Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection. · Recorded from source · Recorded from source
A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
Complete structured claim and evidence
BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.
Engineered thymulin-expression plasmid delivery → Mouse interleukin-10 / Il10 Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_contrast
{"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.
primary_references
Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
source_locator
Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts. · Recorded from source · Recorded from source
A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
Complete structured claim and evidence
Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.
Engineered thymulin-expression plasmid delivery → Mouse regulatory T-cell transcription factor Foxp3 Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
experimental_contrast
{"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Isolated lymphocyte mRNA endpoint; not direct measurement of lineage conversion.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.
primary_references
Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
source_locator
Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated lymphocyte mRNA endpoint; not direct measurement of lineage conversion. · Recorded from source · Recorded from source
A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
Complete structured claim and evidence
Prolactin increased thymulin secretion in human/mouse TEC cultures and thymulin activity in mice.
Prolactin → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "prolactin exposure", "comparator": "Matched experimental control", "endpoint": "Prolactin increased thymulin secretion in human/mouse TEC cultures and thymulin activity in mice.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Prolactin increased thymulin secretion in human/mouse TEC cultures and thymulin activity in mice.
primary_references
Neuroendocrine control of thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. | 1989 | DOI 10.1210/endo-125-1-3 | PMID 2737149 | https://pubmed.ncbi.nlm.nih.gov/2737149/
source_locator
Reviewed reference lines 92-92; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 92–92
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred. · Recorded from source · Recorded from source
| Prolactin | Increased thymulin secretion in human/mouse TEC cultures. In mice, prolactin increased activity; bromocriptine lowered it, and concurrent prolactin restored it. This is an experimental hormone/drug interaction, not proof that every bromocriptine-treated person develops thymulin deficiency. [1989 study](https://pubmed.ncbi.nlm.nih.gov/2737149/) |
Complete structured claim and evidence
GH stimulated thymulin production in TEC preparations; IGF-I or IGF-I-receptor blockade inhibited the GH response.
Human growth hormone → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "growth-hormone exposure", "comparator": "Matched experimental control", "endpoint": "GH stimulated thymulin production in TEC preparations; IGF-I or IGF-I-receptor blockade inhibited the GH response.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
GH stimulated thymulin production in TEC preparations; IGF-I or IGF-I-receptor blockade inhibited the GH response.
primary_references
Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. | 1992 | DOI 10.1210/jcem.75.1.1619008 | PMID 1619008 | https://pubmed.ncbi.nlm.nih.gov/1619008/
source_locator
Reviewed reference lines 93-93; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 93–93
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred. · Recorded from source · Recorded from source
| GH and IGF-I | Both stimulated production in TEC preparations. Blocking IGF-I or its receptor inhibited the GH response, supporting a local IGF-mediated component. The associated human endocrine observations do not isolate that mechanism in vivo. [1992 study](https://pubmed.ncbi.nlm.nih.gov/1619008/) |
Complete structured claim and evidence
IGF-I stimulated thymulin production in TEC preparations.
Human insulin-like growth factor I / IGF1 → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "igf1 exposure", "comparator": "Matched experimental control", "endpoint": "IGF-I stimulated thymulin production in TEC preparations.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
IGF-I stimulated thymulin production in TEC preparations.
primary_references
Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. | 1992 | DOI 10.1210/jcem.75.1.1619008 | PMID 1619008 | https://pubmed.ncbi.nlm.nih.gov/1619008/
source_locator
Reviewed reference lines 93-93; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 93–93
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred. · Recorded from source · Recorded from source
| GH and IGF-I | Both stimulated production in TEC preparations. Blocking IGF-I or its receptor inhibited the GH response, supporting a local IGF-mediated component. The associated human endocrine observations do not isolate that mechanism in vivo. [1992 study](https://pubmed.ncbi.nlm.nih.gov/1619008/) |
Complete structured claim and evidence
T3 restored or stimulated thymulin production in mouse whole-thymus cultures, including a propylthiouracil-associated hypothyroid model; cycloheximide inhibited the response.
T3 → Thymulin Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "triiodothyronine exposure", "comparator": "Matched experimental control", "endpoint": "T3 restored or stimulated thymulin production in mouse whole-thymus cultures, including a propylthiouracil-associated hypothyroid model; cycloheximide inhibited the response.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
T3 restored or stimulated thymulin production in mouse whole-thymus cultures, including a propylthiouracil-associated hypothyroid model; cycloheximide inhibited the response.
primary_references
Neuroendocrine-thymus interactions. I. In vitro modulation of thymic factor secretion by thyroid hormones. | 1990 | DOI 10.1007/bf03349524 | PMID 2184190 | https://pubmed.ncbi.nlm.nih.gov/2184190/
source_locator
Reviewed reference lines 94-94; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 94–94
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Preparations and species as specified in statement and source; no direct iodine/selenium cofactor requirement inferred. · Recorded from source · Recorded from source
| Thyroid hormone | T3 restored/stimulated thymulin production in mouse whole-thymus cultures, including a propylthiouracil-associated hypothyroid model; inhibition by cycloheximide implicated new protein synthesis. This does not identify the peptide precursor. [1990 study](https://pubmed.ncbi.nlm.nih.gov/2184190/) |
Complete structured claim and evidence
Bromocriptine lowered thymulin activity in mice and concurrent prolactin restored it.
Bromocriptine → Mouse thymulin bioassay activity Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Bromocriptine", "comparator": "Control or concurrent prolactin rescue", "endpoint": "Bromocriptine lowered thymulin activity in mice and concurrent prolactin restored it.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Mouse endocrine manipulation; not an established human drug-induced deficiency.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Bromocriptine lowered thymulin activity in mice and concurrent prolactin restored it.
primary_references
Neuroendocrine control of thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. | 1989 | DOI 10.1210/endo-125-1-3 | PMID 2737149 | https://pubmed.ncbi.nlm.nih.gov/2737149/
source_locator
Reviewed reference lines 92-92; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 92–92
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse endocrine manipulation; not an established human drug-induced deficiency. · Recorded from source · Recorded from source
| Prolactin | Increased thymulin secretion in human/mouse TEC cultures. In mice, prolactin increased activity; bromocriptine lowered it, and concurrent prolactin restored it. This is an experimental hormone/drug interaction, not proof that every bromocriptine-treated person develops thymulin deficiency. [1989 study](https://pubmed.ncbi.nlm.nih.gov/2737149/) |
Complete structured claim and evidence
Melatonin accompanied changes in zinc balance, thymulin and IL-2 in stressed tumor-bearing mice; co-movement did not establish thymulin mediation of tumor outcomes.
Melatonin → Mouse thymulin bioassay activity Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Melatonin during stress", "comparator": "Study control", "endpoint": "Melatonin accompanied changes in zinc balance, thymulin and IL-2 in stressed tumor-bearing mice; co-movement did not establish thymulin mediation of tumor outcomes.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Stressed tumor-bearing mouse model.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Melatonin accompanied changes in zinc balance, thymulin and IL-2 in stressed tumor-bearing mice; co-movement did not establish thymulin mediation of tumor outcomes.
primary_references
Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. | 1999 | DOI 10.1016/s0192-0561(98)00067-8 | PMID 10411280 | https://pubmed.ncbi.nlm.nih.gov/10411280/
source_locator
Reviewed reference lines 96-96; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 96–96
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Stressed tumor-bearing mouse model. · Recorded from source · Recorded from source
| Melatonin and stress | In a stressed, tumor-bearing mouse model, melatonin treatment accompanied changes in zinc balance, thymulin and IL-2. Co-movement does not prove a direct melatonin → thymulin receptor pathway or that thymulin mediated the tumor outcome. [1999 study](https://pubmed.ncbi.nlm.nih.gov/10411280/) |
Complete structured claim and evidence
Picomolar zinc-thymulin stimulated ACTH in isolated rat anterior-pituitary tissue with cAMP-associated changes.
Thymulin → Rat anterior-pituitary ACTH release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Picomolar zinc-thymulin", "comparator": "Matched tissue control", "endpoint": "Picomolar zinc-thymulin stimulated ACTH in isolated rat anterior-pituitary tissue with cAMP-associated changes.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Picomolar zinc-thymulin stimulated ACTH in isolated rat anterior-pituitary tissue with cAMP-associated changes.
primary_references
Thymulin stimulates corticotrophin release and cyclic nucleotide formation in the rat anterior pituitary gland. | 1997 | DOI 10.1159/000097322 | PMID 9483196 | https://pubmed.ncbi.nlm.nih.gov/9483196/
source_locator
Reviewed reference lines 104-104; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 104–104
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement. · Recorded from source · Recorded from source
In isolated rat anterior pituitary tissue, picomolar zinc–thymulin stimulated ACTH, accompanied by cAMP changes and cGMP changes at higher tested concentrations. A cAMP-directed phosphodiesterase inhibitor enhanced some responses, whereas the cGMP-directed inhibitor attenuated responses at higher concentrations. LH increased at selected concentrations, **GH did not**, and prolactin decreased. This does not establish human cortisol elevation or blood–brain barrier passage. [1997 study](https://pubmed.ncbi.nlm.nih.gov/9483196/)
Complete structured claim and evidence
GH did not increase in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.
Thymulin → Rat anterior-pituitary growth-hormone release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Picomolar zinc-thymulin", "comparator": "Matched tissue control", "endpoint": "GH did not increase in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
GH did not increase in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.
primary_references
Thymulin stimulates corticotrophin release and cyclic nucleotide formation in the rat anterior pituitary gland. | 1997 | DOI 10.1159/000097322 | PMID 9483196 | https://pubmed.ncbi.nlm.nih.gov/9483196/
source_locator
Reviewed reference lines 104-104; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 104–104
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement. · Recorded from source · Recorded from source
In isolated rat anterior pituitary tissue, picomolar zinc–thymulin stimulated ACTH, accompanied by cAMP changes and cGMP changes at higher tested concentrations. A cAMP-directed phosphodiesterase inhibitor enhanced some responses, whereas the cGMP-directed inhibitor attenuated responses at higher concentrations. LH increased at selected concentrations, **GH did not**, and prolactin decreased. This does not establish human cortisol elevation or blood–brain barrier passage. [1997 study](https://pubmed.ncbi.nlm.nih.gov/9483196/)
Complete structured claim and evidence
Prolactin decreased in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.
Thymulin → Rat anterior-pituitary prolactin release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Picomolar zinc-thymulin", "comparator": "Matched tissue control", "endpoint": "Prolactin decreased in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Prolactin decreased in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.
primary_references
Thymulin stimulates corticotrophin release and cyclic nucleotide formation in the rat anterior pituitary gland. | 1997 | DOI 10.1159/000097322 | PMID 9483196 | https://pubmed.ncbi.nlm.nih.gov/9483196/
source_locator
Reviewed reference lines 104-104; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 104–104
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated rat anterior-pituitary tissue; picomolar zinc-thymulin; concentration-dependent cAMP/cGMP responses. Not human cortisol measurement. · Recorded from source · Recorded from source
In isolated rat anterior pituitary tissue, picomolar zinc–thymulin stimulated ACTH, accompanied by cAMP changes and cGMP changes at higher tested concentrations. A cAMP-directed phosphodiesterase inhibitor enhanced some responses, whereas the cGMP-directed inhibitor attenuated responses at higher concentrations. LH increased at selected concentrations, **GH did not**, and prolactin decreased. This does not establish human cortisol elevation or blood–brain barrier passage. [1997 study](https://pubmed.ncbi.nlm.nih.gov/9483196/)
Complete structured claim and evidence
Higher-concentration thymulin stimulated GH release in dispersed rat pituitary preparations; responses depended on age and concentration.
Thymulin → Rat anterior-pituitary growth-hormone release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin", "comparator": "Matched cell preparation", "endpoint": "Higher-concentration thymulin stimulated GH release in dispersed rat pituitary preparations; responses depended on age and concentration.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Dispersed rat pituitary cells; higher concentration than earlier tissue study; no universal GH sign.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Higher-concentration thymulin stimulated GH release in dispersed rat pituitary preparations; responses depended on age and concentration.
primary_references
Growth hormone-releasing activity of thymulin on pituitary somatotropes is age dependent. | 1999 | DOI 10.1159/000054399 | PMID 9892847 | https://pubmed.ncbi.nlm.nih.gov/9892847/
source_locator
Reviewed reference lines 106-106; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 106–106
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Dispersed rat pituitary cells; higher concentration than earlier tissue study; no universal GH sign. · Recorded from source · Recorded from source
In a different dispersed-rat-pituitary study using higher concentrations, thymulin stimulated **GH** release; responses depended on age and concentration. EGTA blocked activity, and cAMP enhancers potentiated it. These interventions support calcium-sensitive signaling, not a requirement for calcium bound directly to thymulin. The earlier GH null remains part of the evidence. [1999 GH study](https://pubmed.ncbi.nlm.nih.gov/9892847/)
Complete structured claim and evidence
EGTA blocked thymulin-stimulated GH release in dispersed rat pituitary preparations; cAMP enhancers potentiated the response.
EGTA → Rat anterior-pituitary growth-hormone release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_condition
Thymulin without EGTA hormone exposure · Thymulin Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_condition
Thymulin without EGTA chelation · EGTA Condition belongs to the full experimental contrast; do not separate a joint intervention.
experimental_contrast
{"intervention": "EGTA plus thymulin", "comparator": "Thymulin without EGTA", "endpoint": "EGTA blocked thymulin-stimulated GH release in dispersed rat pituitary preparations; cAMP enhancers potentiated the response.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "egta", "state": "chelation"}, {"entity_slug": "thymulin", "state": "hormone exposure"}]} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Rat pituitary preparations; extracellular calcium chelation supports calcium-sensitive signaling, not direct calcium binding to thymulin.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
EGTA blocked thymulin-stimulated GH release in dispersed rat pituitary preparations; cAMP enhancers potentiated the response.
primary_references
Growth hormone-releasing activity of thymulin on pituitary somatotropes is age dependent. | 1999 | DOI 10.1159/000054399 | PMID 9892847 | https://pubmed.ncbi.nlm.nih.gov/9892847/
source_locator
Reviewed reference lines 106-106; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 106–106
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Rat pituitary preparations; extracellular calcium chelation supports calcium-sensitive signaling, not direct calcium binding to thymulin. · Recorded from source · Recorded from source
In a different dispersed-rat-pituitary study using higher concentrations, thymulin stimulated **GH** release; responses depended on age and concentration. EGTA blocked activity, and cAMP enhancers potentiated it. These interventions support calcium-sensitive signaling, not a requirement for calcium bound directly to thymulin. The earlier GH null remains part of the evidence. [1999 GH study](https://pubmed.ncbi.nlm.nih.gov/9892847/)
Complete structured claim and evidence
Thymulin increased prolactin release in a separate rat pituitary experiment, with a bell-shaped response and weaker effects in senescent preparations.
Thymulin → Rat anterior-pituitary prolactin release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin", "comparator": "Matched pituitary preparation", "endpoint": "Thymulin increased prolactin release in a separate rat pituitary experiment, with a bell-shaped response and weaker effects in senescent preparations.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Rat pituitary incubation study; concentration/age dependence, not demonstrated binding to the TRH receptor.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin increased prolactin release in a separate rat pituitary experiment, with a bell-shaped response and weaker effects in senescent preparations.
primary_references
Thymulin stimulates prolactin and thyrotropin release in an age-related manner. | 1998 | DOI 10.1016/s0047-6374(98)00072-4 | PMID 9818729 | https://pubmed.ncbi.nlm.nih.gov/9818729/
source_locator
Reviewed reference lines 108-108; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 108–108
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Rat pituitary incubation study; concentration/age dependence, not demonstrated binding to the TRH receptor. · Recorded from source · Recorded from source
Likewise, a separate study found **prolactin and TSH increases**, with a bell-shaped concentration response in incubation experiments, potentiation by TRH and cAMP-associated interventions, and weaker responses in senescent preparations. EGTA blocked release. The opposite prolactin directions across studies are an unresolved comparison involving concentration and preparation, not grounds to discard either result. TRH-like behavior does not establish binding to the TRH receptor. [1998 prolactin/TSH study](https://pubmed.ncbi.nlm.nih.gov/9818729/)
Complete structured claim and evidence
Thymulin increased TSH release in a separate rat pituitary experiment; TRH and cAMP-associated interventions potentiated responses and EGTA blocked release.
Thymulin → Rat anterior-pituitary TSH release Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Thymulin", "comparator": "Matched pituitary preparation", "endpoint": "Thymulin increased TSH release in a separate rat pituitary experiment; TRH and cAMP-associated interventions potentiated responses and EGTA blocked release.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Rat pituitary incubation study; concentration/age dependence, not demonstrated binding to the TRH receptor.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Thymulin increased TSH release in a separate rat pituitary experiment; TRH and cAMP-associated interventions potentiated responses and EGTA blocked release.
primary_references
Thymulin stimulates prolactin and thyrotropin release in an age-related manner. | 1998 | DOI 10.1016/s0047-6374(98)00072-4 | PMID 9818729 | https://pubmed.ncbi.nlm.nih.gov/9818729/
source_locator
Reviewed reference lines 108-108; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 108–108
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Rat pituitary incubation study; concentration/age dependence, not demonstrated binding to the TRH receptor. · Recorded from source · Recorded from source
Likewise, a separate study found **prolactin and TSH increases**, with a bell-shaped concentration response in incubation experiments, potentiation by TRH and cAMP-associated interventions, and weaker responses in senescent preparations. EGTA blocked release. The opposite prolactin directions across studies are an unresolved comparison involving concentration and preparation, not grounds to discard either result. TRH-like behavior does not establish binding to the TRH receptor. [1998 prolactin/TSH study](https://pubmed.ncbi.nlm.nih.gov/9818729/)
Complete structured claim and evidence
Neonatal thymulin immunoneutralization reduced later circulating LH/FSH in mice; engineered met-FTS protected gonadotropin output in thymus-deficient mice.
Thymulin → Mouse circulating LH and FSH output Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Neonatal thymulin immunoneutralization", "comparator": "Non-neutralized control", "endpoint": "Neonatal thymulin immunoneutralization reduced later circulating LH/FSH in mice; engineered met-FTS protected gonadotropin output in thymus-deficient mice.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Neonatal immunoneutralization and engineered rescue in mouse models; separate from adult dietary depletion.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Neonatal thymulin immunoneutralization reduced later circulating LH/FSH in mice; engineered met-FTS protected gonadotropin output in thymus-deficient mice.
primary_references
Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice. | 2007 | DOI 10.1152/ajpendo.00085.2007 | PMID 17389714 | https://doi.org/10.1152/ajpendo.00085.2007
source_locator
Reviewed reference lines 110-110; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 110–110
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Neonatal immunoneutralization and engineered rescue in mouse models; separate from adult dietary depletion. · Recorded from source · Recorded from source
There is also an experimental loss-of-function result: neonatal thymulin immunoneutralization in mice reduced later circulating LH/FSH, while engineered met-FTS delivery protected gonadotropin output in thymus-deficient mice. This supports a developmental endocrine role in those models; it is not equivalent to adult dietary zinc deficiency or an established human infertility mechanism. [2007 study](https://doi.org/10.1152/ajpendo.00085.2007)
Complete structured claim and evidence
Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content in postmortem thymuses of 58 Senegalese children.
Severe protein-energy malnutrition → Human thymic thymulin content Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Severe protein-energy malnutrition", "comparator": "Study comparison children", "endpoint": "Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content in postmortem thymuses of 58 Senegalese children.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Human postmortem observational comparison; not controlled intervention or proof of zinc loading defect.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content in postmortem thymuses of 58 Senegalese children.
primary_references
Thymulin (facteur thymique serique) and zinc contents of the thymus glands of malnourished children. | 1988 | DOI 10.1093/ajcn/48.2.335 | PMID 3136643 | https://pubmed.ncbi.nlm.nih.gov/3136643/
source_locator
Reviewed reference lines 116-116; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 116–116
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human postmortem observational comparison; not controlled intervention or proof of zinc loading defect. · Recorded from source · Recorded from source
A crucial counterexample comes from postmortem thymuses of 58 Senegalese children. Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content, **without depleted thymic zinc content**. This observational study cannot resolve intracellular zinc delivery, but it shows why reduced thymulin should not automatically be assigned to insufficient total tissue zinc. [Jambon et al., 1988](https://pubmed.ncbi.nlm.nih.gov/3136643/)
Complete structured claim and evidence
Low thymulin content in the child malnutrition study occurred without depleted total thymic zinc; total zinc does not resolve subcellular availability.
Severe protein-energy malnutrition → Human thymic zinc content Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Severe protein-energy malnutrition", "comparator": "Study comparison children", "endpoint": "Low thymulin content in the child malnutrition study occurred without depleted total thymic zinc; total zinc does not resolve subcellular availability.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Human postmortem thymuses, 58 Senegalese children; observational association.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Low thymulin content in the child malnutrition study occurred without depleted total thymic zinc; total zinc does not resolve subcellular availability.
primary_references
Thymulin (facteur thymique serique) and zinc contents of the thymus glands of malnourished children. | 1988 | DOI 10.1093/ajcn/48.2.335 | PMID 3136643 | https://pubmed.ncbi.nlm.nih.gov/3136643/
source_locator
Reviewed reference lines 116-116; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 116–116
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human postmortem thymuses, 58 Senegalese children; observational association. · Recorded from source · Recorded from source
A crucial counterexample comes from postmortem thymuses of 58 Senegalese children. Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content, **without depleted thymic zinc content**. This observational study cannot resolve intracellular zinc delivery, but it shows why reduced thymulin should not automatically be assigned to insufficient total tissue zinc. [Jambon et al., 1988](https://pubmed.ncbi.nlm.nih.gov/3136643/)
Complete structured claim and evidence
The PAT analogue reduced experimental hyperalgesia in rats with changes in inflammatory mediators; this is not native-thymulin analgesic efficacy in humans.
PAT thymulin peptide analogue → Rat experimental hyperalgesia Recorded from sourceungraded
Experimental context and source evidence
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "PAT analogue", "comparator": "Experimental control", "endpoint": "The PAT analogue reduced experimental hyperalgesia in rats with changes in inflammatory mediators; this is not native-thymulin analgesic efficacy in humans.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Rat PAT experiment; analogue kept separate from native peptide and withdrawn hippocampal PAT article.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
The PAT analogue reduced experimental hyperalgesia in rats with changes in inflammatory mediators; this is not native-thymulin analgesic efficacy in humans.
primary_references
Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat. | 2002 | DOI 10.1038/sj.bjp.0704793 | PMID 12110619 | https://pubmed.ncbi.nlm.nih.gov/12110619/
source_locator
Reviewed reference lines 150-150; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 150–150
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Rat PAT experiment; analogue kept separate from native peptide and withdrawn hippocampal PAT article. · Recorded from source · Recorded from source
Native peptide, zinc-loaded preparation, engineered met-FTS expression, PAT and nanoparticles are separate interventions. The PAT rat study supports anti-hyperalgesic activity for that **analogue**, with changes in inflammatory mediators; it does not establish analgesic efficacy of native thymulin in people. [PAT study](https://pubmed.ncbi.nlm.nih.gov/12110619/)
Complete structured claim and evidence
Mild zinc deficiency was accompanied by reduced thymulin bioactivity despite normal plasma zinc in the small human study; repletion or laboratory zinc treatment restored activity.
Zinc → Human circulating thymulin bioassay activity Recorded from sourceungraded
Experimental context and source evidence
availability_state
nutrient_deficiency Imported condition classification; unverified.
evidence_access
Primary bibliographic record and abstract checked; full methods/figures not comprehensively reviewed.
experimental_contrast
{"intervention": "Mild zinc deficiency or controlled dietary depletion", "comparator": "Zinc-replete or repleted comparison", "endpoint": "Mild zinc deficiency was accompanied by reduced thymulin bioactivity despite normal plasma zinc in the small human study; repletion or laboratory zinc treatment restored activity.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
experimental_model
Two dietary-depletion volunteers; six mildly zinc-deficient sickle-cell adults and six without sickle-cell anemia. Not population diagnostic validation.
interpretation_status
Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
limitations
Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
plain_language
Mild zinc deficiency was accompanied by reduced thymulin bioactivity despite normal plasma zinc in the small human study; repletion or laboratory zinc treatment restored activity.
primary_references
Serum thymulin in human zinc deficiency. | 1988 | DOI 10.1172/jci113717 | PMID 3262625 | https://www.jci.org/articles/view/113717
source_locator
Line 1 of the separately retained human zinc/thymulin excerpt; originally in the reviewed thymulin reference.
trigger_kind
nutrient_deficiency Imported condition classification; unverified.
Zinc availability and human thymulin bioactivity: study excerpt · lines 1–1
Exact excerpt from the 3 October 2026 reviewed thymulin reference. Primary study: Prasad et al. 1988, https://www.jci.org/articles/view/113717. Small human proof of concept; not population diagnostic validation. · supports · Two dietary-depletion volunteers; six mildly zinc-deficient sickle-cell adults and six without sickle-cell anemia. Not population diagnostic validation. · Recorded from source · Recorded from source
The strongest small human study included two dietary-depletion volunteers, six mildly zinc-deficient adults with sickle-cell anemia and six without it. Plasma zinc was normal, while cellular zinc assessments suggested deficiency. Thymulin bioactivity fell and recovered with zinc repletion or laboratory zinc treatment; immune readouts also changed. This demonstrates a useful **human proof of concept**, not population-wide diagnostic accuracy or proof that thymulin mediated every benefit of zinc. [Prasad et al., 1988](https://www.jci.org/articles/view/113717)
Complete structured claim and evidence

Availability and dependencies

Each situation shows the normal role first, then what the sources report under a specific condition. A shortfall in the diet, a fault in the machinery, and a low blood reading are kept separate because they are not the same thing.

The sources

Every document behind this chapter is preserved word for word. Open one to read it in full with its recorded conflicts marked in place.

Thymulin: detailed mechanisms of action (reviewed 3 October 2026)Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · Recorded from sourceRead preserved source
Zinc availability and human thymulin bioactivity: study excerptExact excerpt from the 3 October 2026 reviewed thymulin reference. Primary study: Prasad et al. 1988, https://www.jci.org/articles/view/113717. Small human proof of concept; not population diagnostic validation. · Recorded from sourceRead preserved source

Recorded disagreements

Where two sources say different things, both are kept and the difference is explained. You can discuss a disagreement or propose a mechanism that might account for it.

Rat pituitary prolactin: decreases versus increases after thymulinTwo primary studies report opposite prolactin directions in different rat pituitary preparations and concentration regimes. This is a real cross-study comparison, not a correction of the earlier draft. Concentration and preparation are plausible explanations, not established resolution.Read the recorded disagreement

Open questions in this collection

Questions the curators could not answer from the sources in front of them, kept here with the reason each one is still open. These are gaps in this collection, not findings or proof that no one has studied them.

1. **Which part of a low-activity phenotype is metal loading versus reduced production?** Pair peptide measurement with functional recovery and producing-cell measurements. Recovery with zinc in a tube cannot by itself identify the original intracellular defect.Open research question from the reviewed reference; not an established causal claim.
2. **What is the direct binding/transduction machinery?** Historical cell binding and downstream signaling should be joined only after identifying a specific binding partner and demonstrating its functional requirement. Different responsive cell types may not use identical machinery.Open research question from the reviewed reference; not an established causal claim.
3. **Why does thymulin suppress NF-κB in some settings but leave it unchanged in another?** Compare stimulation state, differentiation history, age, zinc matching and response time. Opposite or null results are the starting evidence.Open research question from the reviewed reference; not an established causal claim.
4. **Does metallothionein buffer zinc delivery or limit it under sustained stress?** Resolve liver, plasma and TEC pools and distinguish zinc movement from increased metallothionein expression. The existing associations do not identify the transfer step.Open research question from the reviewed reference; not an established causal claim.
5. **Can total thymic zinc remain adequate while a usable pool is insufficient?** The malnutrition and stress observations motivate this question, but they also leave reduced epithelial mass and altered synthesis as alternatives.Open research question from the reviewed reference; not an established causal claim.
6. **Does endocrine feedback amplify a nutritional disturbance?** GH/IGF, prolactin and thyroid links justify exploring feedback, but pituitary dose-dependent reversals and target-cell aging prevent assigning a universal loop direction.Open research question from the reviewed reference; not an established causal claim.
7. **Does restoring thymulin activity restore useful immunity?** Measure peptide activity separately from thymic output, immune competence and clinical endpoints. Zinc has many targets; mediation requires evidence beyond simultaneous improvement.Open research question from the reviewed reference; not an established causal claim.
8. **Does a functional biomarker identify differential benefit from zinc repletion?** Validate the measurement first, then test a prespecified interaction. No “thymulin fails first” ranking follows from the present data.Open research question from the reviewed reference; not an established causal claim.

Chapters contain source-recorded findings and curated literature summaries. Read each finding's evidence grade, experimental context and review qualifications. The ledger is not medical advice.

Thymulin

The mechanisms

Zinc addition restored classical thymulin rosette-bioassay activity after Chelex metal removal, with best activation at a 1:1 metal-to-peptide ratio.

Purified FTS bound zinc with apparent Kd (5 +/- 2) x 10^-7 M at pH 7.5; binding was undetectable below pH 6 in this assay.

Other tested metals competed for zinc binding to purified FTS; this is not a demonstrated dietary-metal antagonism in vivo.

NMR in DMSO-d6 identified 1:1 and 1:2 zinc-peptide complexes; Ser4 and the Asn9 terminal carboxylate coordinated zinc, with Ser8 participating in the 1:1 complex.

Thymic epithelial cells produce thymulin; metal-dependent antibody recognition must be distinguished from peptide quantity and biological activity.

IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.

IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.

IL-1 alpha and IL-1 beta increased zinc uptake in cultured human thymic epithelial cells; part of the response was independent of proliferation.

IL-1 alpha and IL-1 beta increased secretion of biologically active thymulin from cultured human TECs.

IL-1 increased metallothionein mRNA in human TEC cultures; direct metallothionein-to-FTS zinc transfer remained proposed rather than measured.

Stressed metallothionein-overexpressing mice had reduced active thymulin despite normal-range plasma zinc and preserved zinc-recoverable thymulin activity.

Experimental met-FTS gene delivery expresses an engineered analogue; it does not identify the native human FTS precursor gene.

Radioligand assays found specific FTS-binding sites with apparent Kd near 3 nM in 1301 and HSB2 cells; several other tested cell lines lacked comparable binding.

Induction of IL-2-receptor-positive lymphocytes was used as a functional zinc-thymulin readout; it is not equivalent to IL-2 secretion.

Zinc-thymulin increased nuclear PKC activity in isolated lymphocyte nuclei when IL-1 was present, but not without IL-1.

Thymulin produced opposite IL-2-receptor-positive lymphocyte responses in normal versus hypothyroid chicken strains.

Thymulin increased proinflammatory cytokine secretion in unstimulated RAW264.7 macrophages. In LPS-stimulated cells, thymulin alone did not change the measured cytokine secretion.

Thymulin reduced SAPK/JNK activity in LPS-stimulated RAW264.7 cells.

Thymulin did not reduce the reported NF-kappa-B activation readout in LPS-stimulated RAW264.7 macrophages; this is not evidence for unconditional NF-kappa-B inhibition.

Thymulin increased HSP72 in the macrophage experiment.

Thymulin increased cAMP in LPS-challenged fetal rat alveolar type II cells.

Thymulin reduced NF-kappa-B nuclear signaling in LPS-challenged fetal rat alveolar type II cells.

Thymulin reduced IL-1 beta release in LPS-challenged fetal rat alveolar type II cells.

IL-6 was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.

TNF-alpha was not similarly suppressed by thymulin in LPS-challenged fetal rat alveolar type II cells.

Combined thymulin/zinc increased IL-6 in the developmental lung experiments.

Combined thymulin/zinc reduced TNF protein in the developmental lung experiments; transcript and protein effects must remain separate.

In repeated-LPS mice, free thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.

In repeated-LPS mice, free thymulin reduced reported splenic jnk phosphorylation/signaling readouts.

In repeated-LPS mice, free thymulin reduced reported splenic p38 phosphorylation/signaling readouts.

In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.

In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.

In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.

In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.

The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.

Thymulin with equimolar zinc reduced I-kappa-B-alpha phosphorylation and p65 DNA binding in conditioned mouse macrophages.

Mutation of an NF-kappa-B site in the mouse Il6 reporter removed the inhibitory reporter effect of thymulin treatment.

Thymulin treatment improved antitumor immune responses and anti-PD-L1 responsiveness in aged tumor-bearing mice.

Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.

BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.

Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.

Prolactin increased thymulin secretion in human/mouse TEC cultures and thymulin activity in mice.

GH stimulated thymulin production in TEC preparations; IGF-I or IGF-I-receptor blockade inhibited the GH response.

IGF-I stimulated thymulin production in TEC preparations.

T3 restored or stimulated thymulin production in mouse whole-thymus cultures, including a propylthiouracil-associated hypothyroid model; cycloheximide inhibited the response.

Bromocriptine lowered thymulin activity in mice and concurrent prolactin restored it.

Melatonin accompanied changes in zinc balance, thymulin and IL-2 in stressed tumor-bearing mice; co-movement did not establish thymulin mediation of tumor outcomes.

Picomolar zinc-thymulin stimulated ACTH in isolated rat anterior-pituitary tissue with cAMP-associated changes.

GH did not increase in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.

Prolactin decreased in the picomolar zinc-thymulin isolated rat anterior-pituitary experiment.

Higher-concentration thymulin stimulated GH release in dispersed rat pituitary preparations; responses depended on age and concentration.

EGTA blocked thymulin-stimulated GH release in dispersed rat pituitary preparations; cAMP enhancers potentiated the response.

Thymulin increased prolactin release in a separate rat pituitary experiment, with a bell-shaped response and weaker effects in senescent preparations.

Thymulin increased TSH release in a separate rat pituitary experiment; TRH and cAMP-associated interventions potentiated responses and EGTA blocked release.

Neonatal thymulin immunoneutralization reduced later circulating LH/FSH in mice; engineered met-FTS protected gonadotropin output in thymus-deficient mice.

Severe protein-energy malnutrition was associated with small thymuses and very low thymulin content in postmortem thymuses of 58 Senegalese children.

Low thymulin content in the child malnutrition study occurred without depleted total thymic zinc; total zinc does not resolve subcellular availability.

The PAT analogue reduced experimental hyperalgesia in rats with changes in inflammatory mediators; this is not native-thymulin analgesic efficacy in humans.

Mild zinc deficiency was accompanied by reduced thymulin bioactivity despite normal plasma zinc in the small human study; repletion or laboratory zinc treatment restored activity.

Availability and dependencies

The sources

Recorded disagreements

Open questions in this collection